GlobeNewswire Inc | Jun 3, 2021 08:00AM EDT

June 03, 2021

AUSTIN, Texas, June 03, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Nasdaq: AWH),a bioanalytical-based womens health company focused on gynecologic disease, released the analytical and initial clinical data for OVASightin an abstract titled Serum-based Assay for Adnexal Mass Risk of Ovarian Malignancy. Registrants attending the American Society of Clinical Oncology (ASCO) 2021 virtual meeting gained access to the poster on May 19, 2021, and the on-demand presentation will be released to the ASCO virtual meeting registrants at 9:00 a.m. EDT on June 4, 2021.

OVASight (MIA3G) is third-generation OVA technology and is a laboratory-developed, blood-based pelvic mass risk assessment test for ovarian cancer in a low prevalence population. It was developed to increase specificity, maintain high sensitivity with early-stage disease, and allow for conservative management of women with a suspected benign mass. A total of 596 samples collected from real-world patients were used to validate the OVASight diagnostic algorithm. Validation data demonstrated 89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6% in a low prevalence population (3.8%). In addition, overall sensitivity as well as sensitivity in early-stage disease were significantly better than CA-125 alone. See table below:

MIA3G (OVASight) CA125Overall Sensitivity (All Stages) 21/23 (91.3%) 15/23 (65.2%)Early-Stage (Stage I & II) Sensitivity 10/12 (83.0%) 6/12 (50.0%)

Based on this promising data, we are thrilled with the performance of this new test, stated Elena Ratner, M.D., Global Chief Global Medical Advisor, Clinical and Translational Medicine at Aspira Womens Health. Dr. Ratner further explained that it is important to give providers better tools to help provide personalized risk assessment for women with pelvic masses and expectant management for those masses that are most likely benign.

Below are details of theabstract accepted at ASCO. All posters will be available to ASCO 2021 virtual meeting registrants on-demand beginning at9:00 a.m. EDT on June 4, 2021.

Title: Serum-based assay for adnexal mass risk of ovarian malignancyAbstract 5551#:Authors: Daniel Ure MS, Rowan Bullock BS, Gary Altwerger MD, Elena Ratner MD, Lesley Northrop Ph.D. FACMG

About Aspira Womens Health Inc.Aspira Womens Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1 plus combines our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. The next generation of products in development are OVASightand EndoCheck. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:

Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com